>Mercado de medicamentos inyectables liofilizados de América del Norte, por empaque (viales, jeringas de doble cámara, cartuchos de doble cámara y otros), clase de medicamento (antiinfeccioso, antineoplásico, diuréticos, inhibidor de la bomba de protones, anestésico, anticoagulante, AINE, corticosteroides y otros), forma (polvo y líquido), indicación (oncología, enfermedades autoinmunes, trastornos hormonales, enfermedades respiratorias, trastornos gastrointestinales, trastornos dermatológicos, enfermedades oftálmicas y otros), vía de administración (intravenosa/infusión, intramuscular y otros), usuario final (hospital, clínicas, atención médica domiciliaria y otros), canal de distribución (licitación directa, ventas minoristas y otros), país (EE. UU., Canadá y México) Tendencias de la industria y pronóstico hasta 2028.
Análisis y perspectivas del mercado : mercado de medicamentos inyectables liofilizados de América del Norte
Se espera que el mercado de medicamentos inyectables liofilizados de América del Norte gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 5,7% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 3283,61 millones para 2028. Se espera que el aumento de las enfermedades crónicas en todo el mundo actúe como un motor para impulsar la demanda del mercado de medicamentos inyectables liofilizados.
La liofilización es otro término para denominar a la liofilización. Se trata de una técnica que consiste en aislar un material sólido de un disolvente mediante la congelación y evaporación de la solución al vacío. Se considera que los productos liofilizados tienen una vida útil más larga que los medicamentos convencionales y, por lo tanto, son los más adecuados. La protección de productos biológicos, proteínas, anticuerpos, microorganismos, parenterales, plasma sanguíneo, enzimas, reactivos de diagnóstico, vacunas y nutracéuticos se realiza habitualmente mediante liofilización. Para mantener estables algunos ingredientes a granel inestables, es necesaria la liofilización del inyectable estéril.
Se espera que el creciente avance tecnológico de los medicamentos inyectables liofilizados actúe como un impulsor para impulsar la demanda del mercado de medicamentos inyectables liofilizados. Se espera que el aumento en el número de retiradas de productos de medicamentos liofilizados y el tipo de envase actúen como restricción del mercado de medicamentos inyectables liofilizados. Se espera que el aumento en las aprobaciones regulatorias para medicamentos liofilizados actúe como una oportunidad para impulsar la demanda del mercado de medicamentos inyectables liofilizados. Se espera que los factores asociados con la fabricación de viales liofilizados para productos parenterales desafíen la demanda del mercado de medicamentos inyectables liofilizados.
The lyophilized injectable drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the lyophilized injectable drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America Lyophilized Injectable Drugs Market scope and market size
The North America lyophilized injectable drugs market is categorized into seven notable segments which are based on the packaging, drug class, form, indication, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of packaging, the lyophilized injectable drugs market is segmented into vials, dual-chamber syringes, dual-chamber cartridges and others. In 2021, vials segment is expected to dominate the lyophilized injectable drugs market because the vials are most cost effective than other packaging.
- On the basis of drug class, the lyophilized injectable drugs market is segmented into anti-infective, antineoplastic, diuretics, proton pump inhibitor, anesthetic, anticoagulant, NSAID’s, corticosteroids and others. In 2021, anti-infective segment is expected to dominate the lyophilized injectable drugs market because of the increased demand for the as anti-infective consists of various antibiotics which helps in preventing infection after the surgery.
- On the basis of form, the lyophilized injectable drugs market is segmented into powder and liquid. In 2021, powder segment is expected to dominate the lyophilized injectable drugs market because of it is easy to transport and the chances of microbial growth are very less.
- On the basis of indication, the lyophilized injectable drugs market is segmented into oncology, autoimmune diseases, hormonal disorders, respiratory diseases, gastrointestinal disorders, dermatological disorders, ophthalmic diseases and others. In 2021, oncology segment is expected to dominate the lyophilized injectable drugs market because of this disease is more and the R&D is more focused on developing drugs that are used for oncology.
- On the basis of route of administration, the lyophilized injectable drugs market is segmented into intravenous/infusion, intramuscular and others. In 2021, intravenous/infusion segment is expected to dominate the lyophilized injectable drugs market because of the delivery rate is very high even the volume of the drug is very less.
- On the basis of end user, the lyophilized injectable drugs market is segmented into hospital, clinics, home healthcare and others. In 2021, hospital segment is expected to dominate the lyophilized injectable drugs market due to the funds that are provided to these facilities to take more lyophilised drugs as compared to other end users.
- On the basis of distribution channel, the lyophilized injectable drugs market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the lyophilized injectable drugs market because the key players are mostly tie bonds with these dealers to distribute there drugs.
Lyophilized Injectable Drugs Market Country Level Analysis
North America lyophilized injectable drugs market is analysed and market size information is provided by the country, packaging, drug class, form, indication, route of administration, end user and distribution channel as referenced above.
The countries covered in the North America lyophilized injectable drugs market are U.S., Canada and Mexico.
- In North America, U.S. is expected to dominate the lyophilized injectable drugs market because of increasing demand of lyophilised drugs due to increasing in disease like cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
New product launches by manufactures is Creating New Opportunities for Players in the Lyophilized Injectable Drugs Market
Lyophilized injectable drugs market also provides you with detailed market analysis for every country growth in aesthetic industry with Lyophilized Injectable Drugs Market sales, impact of advancement in the lyophilized injectable drugs market and changes in regulatory scenarios with their support for the market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lyophilized Injectable Drugs Market Share Analysis
El panorama competitivo del mercado de medicamentos inyectables liofilizados proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de medicamentos inyectables liofilizados.
Las principales empresas que ofrecen medicamentos inyectables liofilizados en el mercado de medicamentos inyectables liofilizados de América del Norte son AuroMedics Pharma LLC Pharma LLC (una subsidiaria de Aurobindo Pharma), Astellas Pharma US, Inc. (una subsidiaria de Astellas Pharma Inc.), Aristopharma Ltd., Pfizer Inc., Viatris Inc., Gilead Sciences, Inc., Cirondrugs, Amneal Pharmaceuticals LLC, Jubilant Generics Limited – A Jubilant Pharma Company, Novartis AG, Otsuka America Pharmaceutical, Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Fresenius Kabi USA (una subsidiaria de Fresenius Kabi AG), Sanofi, Celon Laboratories Pvt. Ltd. y Baxter, entre otras. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Muchos lanzamientos de productos y acuerdos también son iniciados por empresas de todo el mundo, lo que también está acelerando el mercado de medicamentos inyectables liofilizados.
Por ejemplo,
- En noviembre de 2019, Novartis AG anunció que había firmado un acuerdo estratégico con Medicines Company, una empresa farmacéutica con sede en EE. UU. Este acuerdo ha fortalecido su innovadora cartera de productos farmacéuticos, lo que ha permitido aumentar las ventas y los ingresos en el mercado.
- En marzo de 2021, Zydus Cadila anunció que había reducido el coste de su medicamento Remdac, una versión genérica de Remdesivir utilizada para los pacientes con COVID-19 en la India. Esta iniciativa estratégica adoptada por la empresa ha aumentado su demanda y sus ventas en el mercado, lo que ha aumentado la credibilidad de la empresa.
Este nuevo producto lanzado por la empresa ha aumentado su cartera de productos de estimación de proteínas en el mercado. La colaboración, las empresas conjuntas y otras estrategias del actor del mercado están mejorando el mercado de la empresa en el mercado de medicamentos inyectables liofilizados, lo que también brinda a la organización el beneficio de mejorar su oferta para el mercado.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PACKAGING LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN CHRONIC HEALTH CONDITIONS
6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE
6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES
6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS
6.1.5 TECHNOLOGICAL ADVANCEMENTS
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLESTICK INJURIES
6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE
6.3 OPPORTUNITIES
6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS
6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS
6.3.3 QUALITY CONCERNS
6.4 CHALLENGES
6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS
6.4.2 TIME-CONSUMING PROCESS AND HIGH COST
7 IMPACT OF COVID-19 ON THE NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT IN DEMAND
7.3 IMPACT ON SUPPLY
7.4 STRATEGIC INITIATIVE
7.5 CONCLUSION
8 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING
8.1 OVERVIEW
8.2 VIALS
8.3 DUAL-CHAMBER SYRINGES
8.4 DUAL-CHAMBER CARTRIDGES
8.5 OTHERS
9 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS
9.1 OVERVIEW
9.2 ANTI-INFECTIVE’S
9.2.1 ANTIBIOTICS
9.2.1.1 Azithromycin
9.2.1.2 Doxycycline
9.2.1.3 Vancomycin
9.2.1.4 Polymyxin B
9.2.1.5 Piperacillin
9.2.1.6 Tazobactam
9.2.1.7 Others
9.2.2 ANTIFUNGAL
9.2.2.1 Mycamine
9.2.2.2 Caspofungin Acetate
9.2.2.3 Isavuconazonium Sulfate
9.2.2.4 Amphotericin
9.2.2.5 Others
9.2.3 ANTIVIRAL
9.2.3.1 Acyclovir
9.2.3.2 Ganciclovir
9.2.3.3 Remdesivir
9.2.3.4 Others
9.2.4 OTHERS
9.3 ANTINEOPLASTIC
9.3.1 METHOTREXATE
9.3.2 GEMCITABINE
9.3.3 CYTARABINE
9.3.4 FLUDARABINE
9.3.5 DOXORUBICIN
9.3.6 OXALIPLATIN
9.3.7 ZOLEDRONIC ACID
9.3.8 OTHERS
9.4 DIURETICS
9.4.1 CHLOROTHIAZIDE
9.4.2 ETHACRYNIC ACID
9.4.3 ACETAZOLAMIDE
9.4.4 OTHERS
9.5 PROTON PUMP INHIBITOR
9.5.1 ESOMEPRAZOLE SODIUM
9.5.2 PANTOPRAZOLE SODIUM
9.5.3 OMEPRAZOLE
9.5.4 OTHERS
9.6 ANESTHETIC
9.6.1 VECURONIUM BROMIDE
9.6.2 SODIUM THIOPENTAL
9.6.3 LIDOCAINE
9.6.4 OTHERS
9.7 ANTICOAGULANT
9.7.1 COUMADIN
9.7.2 UROKINASE
9.7.3 ANTITHROMBIN (RECOMBINANT)
9.7.4 APIXABAN
9.7.5 RIVAROXABAN
9.7.6 OTHERS
9.8 NSAID’S
9.8.1 INDOMETHACIN
9.8.2 IBUPROFEN
9.8.3 DICLOFENAC
9.8.4 KETOROLAC
9.8.5 OTHERS
9.9 CORTICOSTEROIDS
9.9.1 HYDROCORTISONE
9.9.2 METHYLPREDNISOLONE
9.9.3 OTHERS
9.1 OTHERS
10 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM
10.1 OVERVIEW
10.2 POWDER
10.3 LIQUID
11 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.3 AUTOIMMUNE DISEASES
11.4 HORMONAL DISORDERS
11.5 RESPIRATORY DISEASES
11.6 GASTROINTESTINAL DISORDERS
11.7 DERMATOLOGICAL DISORDERS
11.8 OPHTHALMIC DISEASES
11.9 OTHERS
12 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAVENOUS/INFUSION
12.3 INTRAMUSCULAR
12.4 OTHERS
13 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAIL SALES
14.4 OTHERS
15 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 CIPLA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 NOVARTIS AG
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 BAXTER
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ZYDUS CADILA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AFFY PHARMA PVT LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 AMNEAL PHARMACEUTICALS LLC
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ARISTOPHARMA LTD.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 CELON LABORATORIES PVT.LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 CIRONDRUGS
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 GENEX PHARMA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 GILEAD SCIENCES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 OTSUKA AMERICA PHARMACEUTICAL, INC
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SANOFI
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.2 VIATRIS INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tablas
TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS
TABLE 2 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 9 NORTH AMERICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 58 NORTH AMERICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 75 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 76 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 77 U.S. ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 78 U.S. ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 79 U.S. ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 80 U.S. ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 81 U.S. ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 82 U.S. DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 83 U.S. PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 84 U.S. ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 85 U.S. ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 86 U.S. NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 87 U.S. CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 88 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 89 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 90 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 U.S. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 94 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 95 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 96 CANADA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 97 CANADA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 98 CANADA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 99 CANADA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 100 CANADA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 101 CANADA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 102 CANADA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 103 CANADA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 104 CANADA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 105 CANADA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 106 CANADA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 107 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 108 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 109 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 111 CANADA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 112 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 113 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 114 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 115 MEXICO ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 116 MEXICO ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 117 MEXICO ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 118 MEXICO ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 119 MEXICO ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 120 MEXICO DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 121 MEXICO PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 122 MEXICO ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 123 MEXICO ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 124 MEXICO NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 125 MEXICO CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 126 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 127 MEXICOLYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 130 MEXICO LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET
FIGURE 15 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020
FIGURE 16 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE
FIGURE 19 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020
FIGURE 20 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 23 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020
FIGURE 24 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE
FIGURE 27 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020
FIGURE 28 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020
FIGURE 36 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)
FIGURE 44 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)
FIGURE 45 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)
FIGURE 48 NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
